Journal of SAFOMS

Register      Login

VOLUME 5 , ISSUE 2 ( July-December, 2017 ) > List of Articles

RESEARCH ARTICLE

Evaluation of the Role of Ormeloxifene in Abnormal Uterine Bleeding

Ritu Sharma, Savita R Singhal

Citation Information : Sharma R, Singhal SR. Evaluation of the Role of Ormeloxifene in Abnormal Uterine Bleeding. J South Asian Feder Menopause Soc 2017; 5 (2):107-110.

DOI: 10.5005/jp-journals-10032-1117

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim

This is a prospective study to find the effect of ormeloxifene on menstrual blood loss and its side effects in patients with abnormal uterine bleeding (AUB).

Materials and methods

Fifty women in the age group of 30 to 52 years with AUB were enrolled in the study. After baseline assessment, each patient was given 60 mg of ormeloxifene orally twice a week for first 3 months, then once a week for the next 3 months. The patients were followed up after 1, 3, and 6 months. The effect of ormeloxifene was evaluated by a change in the pictorial blood loss assessment chart (PBAC) score, passage of clots during menstruation, hemoglobin level, endometrial thickness (ET), and dysmenorrhea. Side effects of the drug were also noted at each visit; p-value < 0.05 was taken as significant.

Results

There was statistically significant reduction in median PBAC score from baseline 360 to 113, 73, and 41.5 after 1, 3, and 6 months. There was significant reduction in ET, passage of clots, and dysmenorrhea at each visit. Mean hemoglobin level increased significantly by 1.56 gm% after 6 months treatment. Adverse effects included amenorrhea (28%), ovarian cyst (11.3%), nausea (4.5%), headache (2%), and weight gain (4.5%). There was no major side effect requiring termination of treatment.

Conclusion

Ormeloxifene is a safe and efficacious alternative for medical therapy in the management of AUB.

Clinical significance

Ormeloxifene can be used in women with AUB to avoid the side effects of hormonal treatment and unnecessary hysterectomies.

How to cite this article

Sharma R, Singhal SR. Evaluation of the Role of Ormeloxifene in Abnormal Uterine Bleeding. J South Asian Feder Menopause Soc 2017;5(2):107-110.


  1. Abnormal genital tract bleeding. Clin Cornerstone 2000 Feb;3(1):25-35.
  2. Diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol 2012 Jul;120(1):197-206.
  3. Menstrual blood loss: a population study. Variations at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45(3):320-351.
  4. Assessment of menstrual blood loss using a pictorial chart. Br J Obstet Gynaecol 1990 Aug;97(8):734-739.
  5. Abnormal uterine bleeding in pre-menopausal women. SOGC clinical practice guidelines. J Obstet Gynecol Can 2013 May;35(5)473-475.
  6. Clinical pharmacokinetics and interaction of centchroman—a mini review. Contraception 2010 Apr;81(4):275-280.
  7. Distribution and excretion pattern of 14C-labeled centchroman in the rhesus monkeys. Med Sci Res 1992;20:259-260.
  8. The efficacy and safety of ormeloxifene in dysfunctional uterine bleeding. Int J Pharm Bio Sci 2013 Mar-Apr;5(5):18-21.
  9. Efficacy and safety of ormeloxifene in management of menorrhagia: a pilot study. J Obstet Gynaecol Res 2009 Aug;35(4):746-752.
  10. A study of efficacy of ormeloxifene in the pharmacological management of dysfunctional uterine bleeding. J Clin Diagn Res 2013 Nov;7(11):2534-2536.
  11. Ormeloxifene a selective estrogen receptor modulator for treatment of dysfunctional menorrhagia. J Obstet Gynaecol Ind 2004 Jan-Feb;54(1):56-59.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.